<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20816" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Dystrophinopathies</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Morales</surname>
            <given-names>Andres</given-names>
          </name>
          <aff>Stanford University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahajan</surname>
            <given-names>Kunal</given-names>
          </name>
          <aff>Holy Heart Advanced Cardiac Care Centre</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andres Morales declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kunal Mahajan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20816.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>This activity covers a group of X-linked muscle disorders, with their most recognized pathology being Duchenne muscular dystrophy (DMD), followed by Becker muscular dystrophy (BMD) and the relatively new phenotype DMD associated dilated cardiomyopathy (DCM). The most severe phenotype, DMD, usually presents in childhood with a series of developmental motor problems, while BMD, it is a late-onset entity. All pathologies are inherited in an X-linked manner, affecting mainly males; however, females are at risk for DCM. This activity reviews the evaluation and management of dystrophinopathies and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the presentation of Duchenne muscular dystrophy.</p></list-item><list-item><p>Outline the evaluation of a patient with muscular dystrophy.</p></list-item><list-item><p>Summarize the treatment options for muscular dystrophy.</p></list-item><list-item><p>Outline the evaluation and management of dystrophinopathies and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20816&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20816">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20816.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Dystropinopathies are a group of X-linked muscle disorders, with their most recognized pathology being Duchenne muscular dystrophy (DMD), followed by Becker muscular dystrophy&#x000a0;(BMD) and the relatively new phenotype DMD associated dilated cardiomyopathy (DCM). The most severe phenotype, DMD, usually presents in childhood with a series of developmental motor problems, while BMD, it is a late-onset entity.&#x000a0;All pathologies are inherited in an X-linked manner, affecting mainly males, but females can also present with a related condition (DCM).</p>
      </sec>
      <sec id="article-20816.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>DMD is 2.2 MB gene with 79 exons, located&#x000a0;on the X chromosome. Deletions of exons, particularly in the exonic regions 2 to 20 and 44 to 53, comprise 60% to 70% of pathogenic variants.&#x000a0;Dystrophin&#x000a0;is membrane-associated protein in muscle and neurons, part of a protein complex linking cytoskeleton and membrane proteins, who later on bind to extracellular matrix proteins.<xref ref-type="bibr" rid="article-20816.r1">[1]</xref></p>
      </sec>
      <sec id="article-20816.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Prevalence for all age groups in the United States is 1.12 for DMD and 0.36 for BMD. There is a higher predominance in Hispanic individuals.<xref ref-type="bibr" rid="article-20816.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20816.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Dystrophin defect leads to the general disorganization of the dystrophin-associated protein complex, resulting in higher muscular susceptibility for membrane damage caused&#x000a0;by myocyte contractions.&#x000a0;<xref ref-type="bibr" rid="article-20816.r3">[3]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-20816.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histopathology shows variation in fiber size with foci of necrosis, leading to&#x000a0;atrophy, inflammatory cell activation, and fibro-fatty infiltration.<xref ref-type="bibr" rid="article-20816.r4">[4]</xref></p>
      </sec>
      <sec id="article-20816.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Three main phenotypes have been described<xref ref-type="bibr" rid="article-20816.r5">[5]</xref>: DMD, BMD, and DCM, with the first two, sharing symptoms and history, but with an important difference, DMD patients tend to require wheelchair use by age 13, while BMD after age 16 or later.</p>
        <p>
<bold>DMD</bold>
</p>
        <p>Presents in early childhood, delayed motor milestones, most noticeably independent walking and standing from the floor. Consistent with parents' complaints, as well as&#x000a0;gait disturbances (toe walking and flat feet). The main affected area is proximal, leading to difficulty climbing stairs, jumping, running.<xref ref-type="bibr" rid="article-20816.r6">[6]</xref>&#x000a0;The Gower maneuver is both a major clinical finding and a&#x000a0;technique for affected children to stand from seating position on the floor. Calf muscles progressively turned firm due to fat infiltration.</p>
        <p>Cardiomyopathy presents in one-third of individuals by adolescence, turning 100% prevalent in all children at age 18.<xref ref-type="bibr" rid="article-20816.r7">[7]</xref>&#x000a0;</p>
        <p>Some children may present a deficit in executive functioning <xref ref-type="bibr" rid="article-20816.r8">[8]</xref>, leading to decreased visuospatial skills.</p>
        <p>The most common cause of death is respiratory failure or cardiomyopathy.<xref ref-type="bibr" rid="article-20816.r9">[9]</xref></p>
        <p>
<bold>BMD</bold>
</p>
        <p>BMD shows late-onset muscle weakness, sometimes developing symptoms after age 30.<xref ref-type="bibr" rid="article-20816.r10">[10]</xref></p>
        <p>Heart failure due to cardiomyopathy is the most common cause of lethality.<xref ref-type="bibr" rid="article-20816.r11">[11]</xref>&#x000a0;No cognitive impairment evidenced.&#x000a0;</p>
        <p>
<bold>DMD-Associated DCM</bold>
</p>
        <p>Rapidly progressive course, related to ventricular arrhythmias, with no skeletal muscle involvement. Affected females exhibit a mild form around age 40.</p>
      </sec>
      <sec id="article-20816.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Creatine phosphokinase (CK) is the best initial test to perform.&#x000a0;Values to consider DMD are above 10-times normal limits, while for BMD are above 5-times the normal limit. DCM CK values could present in a wide range above normal reference. Other tests that may present with high values are aspartate aminotransferase (AST), alanine aminotransferase (ALT), lactate dehydrogenase (LDH).</p>
        <p>Transaminases could also be from hepatic origin.&#x000a0; In order to differentiate, gamma-glutamyl transferase needs to be ordered. If values are normal, then it is likely to be secondary to a myopathy like DMD.&#x000a0;<xref ref-type="bibr" rid="article-20816.r12">[12]</xref></p>
        <p>The most accurate test is DMD gene deletion-duplication analysis, as 60% to 70% of patients show this abnormality. Should it not be positive on the basis of a strong clinical picture,&#x000a0;sequencing would be recommended&#x000a0;to assess for the rest (20% to 30%).</p>
      </sec>
      <sec id="article-20816.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Specialties to&#x000a0;Involved&#x000a0;after Diagnosis</bold>
</p>
        <p>Physical therapy, developmental specialist, cardiology (age 6), and clinical genetics/counselor are consulted.</p>
        <p>
<bold>Cardiomyopathy</bold>
</p>
        <p>When&#x000a0;left ventricle section fraction&#x000a0;is below 55%, some institutions start angiotensin-converting enzyme (ACE) inhibitors or beta-blockers <xref ref-type="bibr" rid="article-20816.r13">[13]</xref>&#x000a0;to improve left ventricular function. Should there be intolerance to ACE inhibitors, angiotensin II-receptor blockers are similarly effective<xref ref-type="bibr" rid="article-20816.r14">[14]</xref>. When cardiac failure is present, digoxin and diuretics should be added. Cardiac transplant had been recommended for patients with severe cardiomyopathy and mild BMD.</p>
        <p>Patients who develop scoliosis may require bracing and surgery (spinal fusion).</p>
        <p>Corticosteroids have&#x000a0;been proved to improve muscle strength and function. This is, therefore, the main therapy for children younger than 15 years of age, although not recommended for children below age 2.<xref ref-type="bibr" rid="article-20816.r15">[15]</xref>&#x000a0;Therapy can start with either prednisone (0.75 mg/kg per day, maximum 40 mg per day) or deflazacort&#x000a0;(0.9 mg/kg per day, maximum 36 mg per day) when motor skills begin to&#x000a0;decline. To assess efficacy, physicians can perform pulmonary function tests and timed muscle function tests, while also monitoring for side effects Cushing syndrome, short-stature, changes in behavior, gastrointestinal (GI)&#x000a0; symptoms, and osteopenia (increased risk for vertebral or long bone fractures<xref ref-type="bibr" rid="article-20816.r16">[16]</xref>). Should a severe side effect present, particularly excessive weight gain, doses can be decreased by 25% until reaching 50% of the original dose. There&#x000a0;are&#x000a0;conflicting views on the use of corticosteroids on BMD patients, as data supporting benefits are quite limited.</p>
        <p>
<bold>Prevention/Monitoring</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Yearly influenza vaccine</p>
          </list-item>
          <list-item>
            <p>Pneumococcal vaccine (PPS 23)<xref ref-type="bibr" rid="article-20816.r17">[17]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Assess for, in the presence of corticosteroid intake, weight gain, dysphagia, constipation, malnutrition or prior main surgeries</p>
          </list-item>
          <list-item>
            <p>Physical therapy to prevent muscle contractures. Promote daily or regular exercise, but if there is muscle pain, reduce activity intensity or frequency</p>
          </list-item>
          <list-item>
            <p>Monitor for serum calcium, phosphorus, alkaline phosphatase, 25-hydroxyvitamin D (per semester), magnesium, PTH, urine calcium, and creatinine; Dual-energy x-ray absorptiometry&#x000a0;at age three and&#x000a0;annually; spine x-rays; bone age, especially if under corticosteroid therapy<xref ref-type="bibr" rid="article-20816.r18">[18]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Consider biphosphonates if there is a history of symptomatic vertebral fractures, not as prophylaxis</p>
          </list-item>
          <list-item>
            <p>Cardiac evaluation every two years, from the time of diagnosis (electrocardiogram and echocardiogram or cardiac MRI)<xref ref-type="bibr" rid="article-20816.r19">[19]</xref><xref ref-type="bibr" rid="article-20816.r18">[18]</xref>;&#x000a0;On heterozygous asymptomatic females, observation, and work up as considered by symptoms; routine cardiac&#x000a0;surveillance every five years from age 25</p>
          </list-item>
          <list-item>
            <p>Baseline pulmonary function tests and biannually along with pediatric pulmonologist if the patient uses a wheelchair, age 12, or has a reduction of vital capacity of less than 80%</p>
          </list-item>
          <list-item>
            <p>Family members or caregivers should be educated regarding manual ventilation bag, mechanical insufflation-exsufflation device.</p>
          </list-item>
        </list>
        <p>
<bold>Contraindications</bold>
</p>
        <p>The use of botulinum toxin is contraindicated. Non-depolarizing anesthetics or&#x000a0;succinylcholine are also contraindicated despite no increased risk for malignant hyperthermia; a small subset has been reported&#x000a0;to show severe malignant hyperthermia-like reactions.<xref ref-type="bibr" rid="article-20816.r20">[20]</xref></p>
      </sec>
      <sec id="article-20816.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p><italic toggle="yes">Emery-Dreifuss muscular dystrophy: </italic>There is a triad of childhood joint contractures, slowly progressive muscle weakness, and initial wasting in humeroperoneal distribution extending to scapular and pelvic girdle muscles. Cardiac involvement can occur after the second decade of life. Limb-girdle muscular dystrophy: This is an autosomal recessive or dominant with a defect on genes encoding sarcoglycans&#x000a0;</p>
        <p><italic toggle="yes">Spinal muscular atrophy:</italic> Shows reduced muscle tone, weakness (sparing facial muscles), anterior horn cell involvement manifesting as tongue fasciculations, and absent deep tendon reflexes. Onset is from birth to adolescence</p>
        <p><italic toggle="yes">Barth syndrome:</italic> This condition is X-linked of the&#x000a0;<italic toggle="yes">TAZ</italic> gene. Cardiomyopathy, neutropenia, skeletal myopathy, prepubertal growth delay occur.</p>
      </sec>
      <sec id="article-20816.s11" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>To date, there are several therapies under investigation, from gene repair and therapy to drugs affecting the expression of dystrophin. Eteplirsen is one of the latter. Approved by the FDA for infusion in 2016, it works by skipping exon 51 during pre-mRNA&#x000a0;splicing correcting dystrophin expression.<xref ref-type="bibr" rid="article-20816.r21">[21]</xref>&#x000a0;Ataluren is another drug on trials, with the goal of bypassing pathogenic variants through promoting ribosomal read-through, therefore continuing dystrophin expression.<xref ref-type="bibr" rid="article-20816.r22">[22]</xref></p>
      </sec>
      <sec id="article-20816.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>
<bold>Genotype Correlations</bold>
</p>
        <p>The difference between phenotypes (DMD and BMD), relies on a reading frame rule, stating that if the pathogenic variant does not alter the reading frame, then the expression will be milder, i.e., BMD; while, on the contrary, should express as DMD (severe phenotype).<xref ref-type="bibr" rid="article-20816.r23">[23]</xref>&#x000a0;This prediction is about 92% accurate.</p>
        <p>DMD-associated DCM involve pathogenic variants affecting the muscle promoter and first exon.</p>
      </sec>
      <sec id="article-20816.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>There are several genetically inherited muscular dystrophy disorders, which are progressive and have no cure. Because of the high morbidity and mortality, these disorders are best managed by an interprofessional team that includes a neurologist, physical therapist, internist, pediatrician, and a geneticist. Many of these patients develop severe motor problems and either become bedridden or must use&#x000a0;a wheelchair. It is important to involve social workers early in their treatment to help improve the home environment and the quality of life. Rehabilitation and neuroscience nurses participate in patient care and report changes to the team. Pharmacists review medication, educate families about proper administration and side effects and monitor compliance. [Level 5]</p>
      </sec>
      <sec id="article-20816.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20816&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20816">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/genetic-disorders/dystrophinopathies/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=20816">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20816/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20816">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20816.s15">
        <title>References</title>
        <ref id="article-20816.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Takeshima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yagi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okizuka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Awano</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yamauchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nishio</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Matsuo</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center.</article-title>
            <source>J Hum Genet</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>55</volume>
            <issue>6</issue>
            <fpage>379</fpage>
            <page-range>379-88</page-range>
            <pub-id pub-id-type="pmid">20485447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <article-title>Romitti et al. Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics. 2015;135(3):513-521.</article-title>
            <source>Pediatrics</source>
            <year>2015</year>
            <month>May</month>
            <volume>135</volume>
            <issue>5</issue>
            <fpage>945</fpage>
            <pub-id pub-id-type="pmid">25934896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>D'Amario</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gowran</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Canonico</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Castiglioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Rovina</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Spinelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Adorisio</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amodeo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perrucci</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Borovac</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pompilio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Crea</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Dystrophin Cardiomyopathies: Clinical Management, Molecular Pathogenesis and Evolution towards Precision Medicine.</article-title>
            <source>J Clin Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>19</day>
            <volume>7</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">30235804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffman</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Fischbeck</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Medori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Loike</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Waterston</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brooke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Specht</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy.</article-title>
            <source>N Engl J Med</source>
            <year>1988</year>
            <month>May</month>
            <day>26</day>
            <volume>318</volume>
            <issue>21</issue>
            <fpage>1363</fpage>
            <page-range>1363-8</page-range>
            <pub-id pub-id-type="pmid">3285207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muntoni</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Torelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferlini</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Dystrophin and mutations: one gene, several proteins, multiple phenotypes.</article-title>
            <source>Lancet Neurol</source>
            <year>2003</year>
            <month>Dec</month>
            <volume>2</volume>
            <issue>12</issue>
            <fpage>731</fpage>
            <page-range>731-40</page-range>
            <pub-id pub-id-type="pmid">14636778</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>QX</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Clinical and pathological features of 50 children with Duchenne's muscular dystrophy].</article-title>
            <source>Zhongguo Dang Dai Er Ke Za Zhi</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>746</fpage>
            <page-range>746-50</page-range>
            <pub-id pub-id-type="pmid">23092565</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beggs</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>Dystrophinopathy, the expanding phenotype. Dystrophin abnormalities in X-linked dilated cardiomyopathy.</article-title>
            <source>Circulation</source>
            <year>1997</year>
            <month>May</month>
            <day>20</day>
            <volume>95</volume>
            <issue>10</issue>
            <fpage>2344</fpage>
            <page-range>2344-7</page-range>
            <pub-id pub-id-type="pmid">9170393</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Battini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chieffo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bulgheroni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Piccini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pecini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lucibello</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lenzi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moriconi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Astrea</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Baranello</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alfieri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vicari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cioni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mercuri</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Cognitive profile in Duchenne muscular dystrophy boys without intellectual disability: The role of executive functions.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>2</issue>
            <fpage>122</fpage>
            <page-range>122-128</page-range>
            <pub-id pub-id-type="pmid">29305139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hermans</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Merkies</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>de Die-Smulders</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Crijns</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Faber</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Hereditary muscular dystrophies and the heart.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>8</issue>
            <fpage>479</fpage>
            <page-range>479-92</page-range>
            <pub-id pub-id-type="pmid">20627570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koyama</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nanba</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohori</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years.</article-title>
            <source>Eur Neurol</source>
            <year>1999</year>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>145</fpage>
            <page-range>145-9</page-range>
            <pub-id pub-id-type="pmid">10529540</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cox</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Kunkel</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Dystrophies and heart disease.</article-title>
            <source>Curr Opin Cardiol</source>
            <year>1997</year>
            <month>May</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-43</page-range>
            <pub-id pub-id-type="pmid">9243091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMillan</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Gregas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Darras</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Kang</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Serum transaminase levels in boys with Duchenne and Becker muscular dystrophy.</article-title>
            <source>Pediatrics</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>127</volume>
            <issue>1</issue>
            <fpage>e132</fpage>
            <page-range>e132-6</page-range>
            <pub-id pub-id-type="pmid">21149430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jefferies</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Eidem</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Belmont</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Craigen</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Ware</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fernbach</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Neish</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy.</article-title>
            <source>Circulation</source>
            <year>2005</year>
            <month>Nov</month>
            <day>01</day>
            <volume>112</volume>
            <issue>18</issue>
            <fpage>2799</fpage>
            <page-range>2799-804</page-range>
            <pub-id pub-id-type="pmid">16246949</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Flanigan</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Thrush</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Dvorchik</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Canter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Parrish</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Braunlin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colan</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Darras</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mendell</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy.</article-title>
            <source>PLoS Curr</source>
            <year>2013</year>
            <month>Dec</month>
            <day>12</day>
            <volume>5</volume>
            <pub-id pub-id-type="pmid">24459612</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moxley</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Ashwal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pandya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Florence</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baumbach</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sussman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wade</surname>
                <given-names>C</given-names>
              </name>
              <collab>Quality Standards Subcommittee of the American Academy of Neurology</collab>
              <collab>Practice Committee of the Child Neurology Society</collab>
            </person-group>
            <article-title>Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.</article-title>
            <source>Neurology</source>
            <year>2005</year>
            <month>Jan</month>
            <day>11</day>
            <volume>64</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-20</page-range>
            <pub-id pub-id-type="pmid">15642897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>King</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Ruttencutter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nagaraja</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Matkovic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Landoll</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoyle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mendell</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kissel</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.</article-title>
            <source>Neurology</source>
            <year>2007</year>
            <month>May</month>
            <day>08</day>
            <volume>68</volume>
            <issue>19</issue>
            <fpage>1607</fpage>
            <page-range>1607-13</page-range>
            <pub-id pub-id-type="pmid">17485648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finder</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Birnkrant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Carl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Farber</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Gozal</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Iannaccone</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Kovesi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kravitz</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Panitch</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schramm</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schroth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sievers</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Sterni</surname>
                <given-names>L</given-names>
              </name>
              <collab>American Thoracic Society</collab>
            </person-group>
            <article-title>Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2004</year>
            <month>Aug</month>
            <day>15</day>
            <volume>170</volume>
            <issue>4</issue>
            <fpage>456</fpage>
            <page-range>456-65</page-range>
            <pub-id pub-id-type="pmid">15302625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bushby</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Finkel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Birnkrant</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Case</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Clemens</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Cripe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kaul</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kinnett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>McDonald</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pandya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poysky</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tomezsko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Constantin</surname>
                <given-names>C</given-names>
              </name>
              <collab>DMD Care Considerations Working Group</collab>
            </person-group>
            <article-title>Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.</article-title>
            <source>Lancet Neurol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>177</fpage>
            <page-range>177-89</page-range>
            <pub-id pub-id-type="pmid">19945914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Towbin</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>A noninvasive means of detecting preclinical cardiomyopathy in Duchenne muscular dystrophy?</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2003</year>
            <month>Jul</month>
            <day>16</day>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>317</fpage>
            <page-range>317-8</page-range>
            <pub-id pub-id-type="pmid">12875770</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bamaga</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Riazi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Amburgey</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Halliday</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Diamandis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guerguerian</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Dowling</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Yoon</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>3</issue>
            <fpage>201</fpage>
            <page-range>201-6</page-range>
            <pub-id pub-id-type="pmid">26951757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>EL</given-names>
              </name>
            </person-group>
            <article-title>Antisense Oligonucleotides for Duchenne Muscular Dystrophy: Why No Neurologist Should Skip This.</article-title>
            <source>JAMA Neurol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>259</fpage>
            <page-range>259-60</page-range>
            <pub-id pub-id-type="pmid">26746046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Finkel</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).</article-title>
            <source>J Child Neurol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>25</volume>
            <issue>9</issue>
            <fpage>1158</fpage>
            <page-range>1158-64</page-range>
            <pub-id pub-id-type="pmid">20519671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20816.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monaco</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Bertelson</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Liechti-Gallati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moser</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kunkel</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus.</article-title>
            <source>Genomics</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-5</page-range>
            <pub-id pub-id-type="pmid">3384440</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
